Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against < em > Candida albicans < /em > Infections: An In Vitro and In Vivo Study
Curr Issues Mol Biol. 2022 Nov 1;44(11):5379-5389. doi: 10.3390/cimb44110364.ABSTRACTCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental can...
Source: Current Issues in Molecular Biology - November 10, 2022 Category: Molecular Biology Authors: Juliana de C Fenley Patr ícia P de Barros Paulo H F do Carmo Ma íra T Garcia Rodnei D Rossoni Juliana C Junqueira Source Type: research
Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against < em > Candida albicans < /em > Infections: An In Vitro and In Vivo Study
Curr Issues Mol Biol. 2022 Nov 1;44(11):5379-5389. doi: 10.3390/cimb44110364.ABSTRACTCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental can...
Source: Mol Biol Cell - November 10, 2022 Category: Molecular Biology Authors: Juliana de C Fenley Patr ícia P de Barros Paulo H F do Carmo Ma íra T Garcia Rodnei D Rossoni Juliana C Junqueira Source Type: research
Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against < em > Candida albicans < /em > Infections: An In Vitro and In Vivo Study
Curr Issues Mol Biol. 2022 Nov 1;44(11):5379-5389. doi: 10.3390/cimb44110364.ABSTRACTCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental can...
Source: Current Issues in Molecular Biology - November 10, 2022 Category: Molecular Biology Authors: Juliana de C Fenley Patr ícia P de Barros Paulo H F do Carmo Ma íra T Garcia Rodnei D Rossoni Juliana C Junqueira Source Type: research
Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against < em > Candida albicans < /em > Infections: An In Vitro and In Vivo Study
Curr Issues Mol Biol. 2022 Nov 1;44(11):5379-5389. doi: 10.3390/cimb44110364.ABSTRACTCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental can...
Source: Current Issues in Molecular Biology - November 10, 2022 Category: Molecular Biology Authors: Juliana de C Fenley Patr ícia P de Barros Paulo H F do Carmo Ma íra T Garcia Rodnei D Rossoni Juliana C Junqueira Source Type: research
Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against < em > Candida albicans < /em > Infections: An In Vitro and In Vivo Study
Curr Issues Mol Biol. 2022 Nov 1;44(11):5379-5389. doi: 10.3390/cimb44110364.ABSTRACTCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental can...
Source: Current Issues in Molecular Biology - November 10, 2022 Category: Molecular Biology Authors: Juliana de C Fenley Patr ícia P de Barros Paulo H F do Carmo Ma íra T Garcia Rodnei D Rossoni Juliana C Junqueira Source Type: research
Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against < em > Candida albicans < /em > Infections: An In Vitro and In Vivo Study
Curr Issues Mol Biol. 2022 Nov 1;44(11):5379-5389. doi: 10.3390/cimb44110364.ABSTRACTCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental can...
Source: Current Issues in Molecular Biology - November 10, 2022 Category: Molecular Biology Authors: Juliana de C Fenley Patr ícia P de Barros Paulo H F do Carmo Ma íra T Garcia Rodnei D Rossoni Juliana C Junqueira Source Type: research
Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against < em > Candida albicans < /em > Infections: An In Vitro and In Vivo Study
Curr Issues Mol Biol. 2022 Nov 1;44(11):5379-5389. doi: 10.3390/cimb44110364.ABSTRACTCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental can...
Source: Current Issues in Molecular Biology - November 10, 2022 Category: Molecular Biology Authors: Juliana de C Fenley Patr ícia P de Barros Paulo H F do Carmo Ma íra T Garcia Rodnei D Rossoni Juliana C Junqueira Source Type: research
Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against < em > Candida albicans < /em > Infections: An In Vitro and In Vivo Study
Curr Issues Mol Biol. 2022 Nov 1;44(11):5379-5389. doi: 10.3390/cimb44110364.ABSTRACTCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental can...
Source: Current Issues in Molecular Biology - November 10, 2022 Category: Molecular Biology Authors: Juliana de C Fenley Patr ícia P de Barros Paulo H F do Carmo Ma íra T Garcia Rodnei D Rossoni Juliana C Junqueira Source Type: research
Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against < em > Candida albicans < /em > Infections: An In Vitro and In Vivo Study
Curr Issues Mol Biol. 2022 Nov 1;44(11):5379-5389. doi: 10.3390/cimb44110364.ABSTRACTCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental can...
Source: Current Issues in Molecular Biology - November 10, 2022 Category: Molecular Biology Authors: Juliana de C Fenley Patr ícia P de Barros Paulo H F do Carmo Ma íra T Garcia Rodnei D Rossoni Juliana C Junqueira Source Type: research
Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against < em > Candida albicans < /em > Infections: An In Vitro and In Vivo Study
Curr Issues Mol Biol. 2022 Nov 1;44(11):5379-5389. doi: 10.3390/cimb44110364.ABSTRACTCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental can...
Source: Current Issues in Molecular Biology - November 10, 2022 Category: Molecular Biology Authors: Juliana de C Fenley Patr ícia P de Barros Paulo H F do Carmo Ma íra T Garcia Rodnei D Rossoni Juliana C Junqueira Source Type: research
Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against < em > Candida albicans < /em > Infections: An In Vitro and In Vivo Study
Curr Issues Mol Biol. 2022 Nov 1;44(11):5379-5389. doi: 10.3390/cimb44110364.ABSTRACTCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental can...
Source: Current Issues in Molecular Biology - November 10, 2022 Category: Molecular Biology Authors: Juliana de C Fenley Patr ícia P de Barros Paulo H F do Carmo Ma íra T Garcia Rodnei D Rossoni Juliana C Junqueira Source Type: research
Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against < em > Candida albicans < /em > Infections: An In Vitro and In Vivo Study
Curr Issues Mol Biol. 2022 Nov 1;44(11):5379-5389. doi: 10.3390/cimb44110364.ABSTRACTCandida albicans is the chief etiological agent of candidiasis, a mycosis prevalent in individuals with acquired immunodeficiency syndrome (AIDS). In recent years, the introduction of human immunodeficiency virus (HIV) protease inhibitors (HIV-PI) has reduced the prevalence of candidiasis in these patients. Seeking new therapeutic strategies based on the perspective of drug repositioning, we evaluated the effects of two second-generation HIV-PIs, atazanavir (ATV) and darunavir (DRV), on virulence factors of C. albicans and experimental can...
Source: Current Issues in Molecular Biology - November 10, 2022 Category: Molecular Biology Authors: Juliana de C Fenley Patr ícia P de Barros Paulo H F do Carmo Ma íra T Garcia Rodnei D Rossoni Juliana C Junqueira Source Type: research
Organic solvents aggregating and shaping structural folding of protein, a case study of the protease enzyme
Biophys Chem. 2022 Dec;291:106909. doi: 10.1016/j.bpc.2022.106909. Epub 2022 Oct 18.ABSTRACTLow solubility of reactants or products in aqueous solutions can result in the enzymatic catalytic reactions that can occur in non-aqueous solutions. In current study we investigated aqueous solutions containing different organic solvents / deep eutectic solvents (DESs) that can influence the protease enzyme's activity, structural, and thermal stabilities. Retroviral aspartic protease enzyme is responsible for the cleavage of the polypeptide precursors into mature viral components, a very crucial step for virus life cycle. In molecu...
Source: Biophysical Chemistry - November 4, 2022 Category: Chemistry Authors: Monikaben Padariya Maciej Baginski Minofar Babak Umesh Kalathiya Source Type: research
Organic solvents aggregating and shaping structural folding of protein, a case study of the protease enzyme
Biophys Chem. 2022 Dec;291:106909. doi: 10.1016/j.bpc.2022.106909. Epub 2022 Oct 18.ABSTRACTLow solubility of reactants or products in aqueous solutions can result in the enzymatic catalytic reactions that can occur in non-aqueous solutions. In current study we investigated aqueous solutions containing different organic solvents / deep eutectic solvents (DESs) that can influence the protease enzyme's activity, structural, and thermal stabilities. Retroviral aspartic protease enzyme is responsible for the cleavage of the polypeptide precursors into mature viral components, a very crucial step for virus life cycle. In molecu...
Source: Biophysical Chemistry - November 4, 2022 Category: Chemistry Authors: Monikaben Padariya Maciej Baginski Minofar Babak Umesh Kalathiya Source Type: research
Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance
We describe design and syntheses of a new generation of exceptionally highly potent non-peptidic HIV-1 protease inhibitors. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Chem. Commun. latest articles)
Source: RSC - Chem. Commun. latest articles - October 6, 2022 Category: Chemistry Authors: Arun K. Ghosh Source Type: research
